Royal Bank of Canada Reduces Stock Position in Astrana Health, Inc. $ASTH

Royal Bank of Canada cut its holdings in Astrana Health, Inc. (NASDAQ:ASTHFree Report) by 97.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,438 shares of the company’s stock after selling 66,556 shares during the period. Royal Bank of Canada’s holdings in Astrana Health were worth $35,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. 325 Capital LLC raised its holdings in Astrana Health by 54.0% during the 4th quarter. 325 Capital LLC now owns 1,839,076 shares of the company’s stock valued at $45,627,000 after acquiring an additional 645,123 shares during the period. State Street Corp boosted its holdings in shares of Astrana Health by 6.2% in the fourth quarter. State Street Corp now owns 1,675,516 shares of the company’s stock worth $41,570,000 after acquiring an additional 98,064 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Astrana Health by 12.5% in the first quarter. Dimensional Fund Advisors LP now owns 1,368,079 shares of the company’s stock valued at $33,545,000 after purchasing an additional 152,267 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Astrana Health by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 1,028,168 shares of the company’s stock valued at $25,513,000 after purchasing an additional 12,212 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in shares of Astrana Health by 418.3% during the 4th quarter. Wellington Management Group LLP now owns 738,853 shares of the company’s stock valued at $18,331,000 after purchasing an additional 596,293 shares during the period. 52.77% of the stock is currently owned by hedge funds and other institutional investors.

Astrana Health Trading Down 1.9%

Shares of ASTH stock opened at $37.83 on Friday. The company has a market capitalization of $2.11 billion, a PE ratio of 46.13 and a beta of 0.90. Astrana Health, Inc. has a 52-week low of $18.08 and a 52-week high of $51.60. The business’s fifty day moving average is $41.07 and its 200 day moving average is $34.62. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.23 and a current ratio of 1.23.

Astrana Health (NASDAQ:ASTHGet Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.34 by $0.46. The business had revenue of $972.52 million during the quarter, compared to analysts’ expectations of $985.62 million. Astrana Health had a return on equity of 10.30% and a net margin of 1.05%.The firm’s revenue was up 48.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.19 earnings per share. On average, equities research analysts anticipate that Astrana Health, Inc. will post 1.32 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Truist Financial increased their price objective on Astrana Health from $47.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, August 10th. TD Cowen lifted their target price on Astrana Health from $45.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Robert W. Baird set a $45.00 price target on Astrana Health in a research report on Friday, May 8th. Barclays increased their price target on shares of Astrana Health from $50.00 to $53.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Finally, Wall Street Zen lowered shares of Astrana Health from a “buy” rating to a “hold” rating in a research report on Sunday, August 16th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $49.43.

View Our Latest Report on ASTH

Astrana Health Profile

(Free Report)

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.

Featured Articles

Institutional Ownership by Quarter for Astrana Health (NASDAQ:ASTH)

Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.